Glucagonoma secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment.<ref name="pmid23681843">{{cite journal| author=Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M et al.| title=Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. | journal=J Gen Intern Med | year= 2013 | volume= 28 | issue= 11 | pages= 1525-9 | pmid=23681843 | doi=10.1007/s11606-013-2490-5 | pmc=PMC3797362 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23681843  }} </ref>
Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment.
==Secondary Prevention==
==Secondary Prevention==
Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at 3 and 6 months post-resection, and every 6 to 12 months thereafter.<ref name="pmid23681843">{{cite journal| author=Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M et al.| title=Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. | journal=J Gen Intern Med | year= 2013 | volume= 28 | issue= 11 | pages= 1525-9 | pmid=23681843 | doi=10.1007/s11606-013-2490-5 | pmc=PMC3797362 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23681843  }} </ref>
Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at 3 and 6 months post-resection, and every 6 to 12 months thereafter.<ref name="pmid23681843">{{cite journal| author=Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M et al.| title=Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. | journal=J Gen Intern Med | year= 2013 | volume= 28 | issue= 11 | pages= 1525-9 | pmid=23681843 | doi=10.1007/s11606-013-2490-5 | pmc=PMC3797362 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23681843  }} </ref>

Revision as of 18:55, 1 August 2017

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma secondary prevention

CDC on Glucagonoma secondary prevention

Glucagonoma secondary prevention in the news

Blogs on Glucagonoma secondary prevention

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment.

Secondary Prevention

Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at 3 and 6 months post-resection, and every 6 to 12 months thereafter.[1]

References

  1. Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M; et al. (2013). "Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome". J Gen Intern Med. 28 (11): 1525–9. doi:10.1007/s11606-013-2490-5. PMC 3797362. PMID 23681843.


Template:WikiDoc Sources